Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 14/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 12/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.43 |
| ▸ | USP2 | O75604 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | TSHR | P16473 | 7/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21878012 | 0.94 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2C19CYP2C9USP2 | |
| SCHEMBL21877989 | 0.90 | CYP1A2 (0.42) | CYP1A2CYP3A4CYP2C19CYP2C9USP2 | |
| SCHEMBL21878042 | 0.88 | CYP1A2 (0.43) | CYP1A2CYP3A4CYP2C19CYP2C9USP2 | |
| SCHEMBL21877945 | 0.87 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C19CYP2C9USP2 | |
| SCHEMBL21877979 | 0.86 | TP53 (0.39) | CYP1A2CYP3A4CYP2C19CYP2C9USP2 | |
| SCHEMBL21878047 | 0.86 | TSHR (0.41) | CYP1A2CYP3A4CYP2C19CYP2C9USP2 | |
| SCHEMBL21878014 | 0.85 | TP53 (0.39) | CYP1A2CYP3A4CYP2C19TSHRCYP2D6 | |
| SCHEMBL21878125 | 0.85 | CYP3A4 (0.39) | CYP1A2CYP3A4CYP2C19CYP2C9USP2 | |
| SCHEMBL21878070 | 0.85 | CYP1A2 (0.41) | CYP1A2CYP3A4CYP2C19CYP2C9USP2 | |
| SCHEMBL21878062 | 0.83 | RAB9A (0.43) | CYP1A2CYP3A4CYP2C19TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883420-B2 | Sting agonists for treating bladder cancer and solid tumors | Venenum Biodesign, LLC (US) | 2024-01-30 | — | — | US | disclosed |
| EP-3873484-B1 | NOVEL STING AGONISTS | VENENUM BIODESIGN LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220048936-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210290645-A1 | STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS | Venenum Biodesign, LLC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11110106-B2 | Sting agonists for treating bladder cancer and solid tumors | Venenum Biodesign, LLC (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210060041-A1 | STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS | Venenum Biodesign, LLC (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131209-A1 | NOVEL STING AGONISTS | STING1, CGAS, TBK1 | CYP1A2 3470/4885CYP3A4 3150/4885CYP2C19 3946/4885 |
| US-20210290645-A1 | STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS | STING1, CGAS, TBK1 | CYP1A2 4509/4885CYP3A4 4503/4885CYP2C19 4268/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | CYP1A2 3075/4885CYP3A4 2736/4885CYP2C19 3872/4885 |
| US-11883420-B2 | Sting agonists for treating bladder cancer and solid tumors | STING1, CGAS, TBK1 | CYP1A2 4509/4885CYP3A4 4503/4885CYP2C19 4268/4885 |
| US-20210060041-A1 | STING AGONISTS FOR TREATING BLADDER CANCER AND SOLID TUMORS | STING1, CGAS, TBK1 | CYP1A2 4509/4885CYP3A4 4503/4885CYP2C19 4268/4885 |
| US-11110106-B2 | Sting agonists for treating bladder cancer and solid tumors | STING1, CGAS, TBK1 | CYP1A2 4509/4885CYP3A4 4503/4885CYP2C19 4268/4885 |
| US-20220048936-A1 | NOVEL STING AGONISTS | STING1, IRF3, CGAS | CYP1A2 3244/4885CYP3A4 3032/4885CYP2C19 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.